The Infectious Diseases Society of America’s 10 × ’20 Initiative (10 New Systemic Antibacterial Agents US Food and Drug Administration Approved by 2020): Is 20 × ’20 a Possibility?-Reference-Cited by-同舟云学术

The Infectious Diseases Society of America’s 10 × ’20 Initiative (10 New Systemic Antibacterial Agents US Food and Drug Administration Approved by 2020): Is 20 × ’20 a Possibility?

Published:2019-02-01 Issue:1 Volume:69 Page:1-11
ISSN:1058-4838
Container-title:Clinical Infectious Diseases
language:en
Short-container-title:

Author:

Talbot George H¹,Jezek Amanda²,Murray Barbara E³,Jones Ronald N⁴,Ebright Richard H⁵,Nau Gerard J⁶,Rodvold Keith A⁷,Newland Jason G⁸,Boucher Helen W⁹,

Affiliation:

1. Talbot Advisors LLC, Anna Maria, Florida

2. Infectious Diseases Society of America, Arlington, Virginia

3. Division of Infectious Diseases, McGovern Medical School at the University of Texas Health Science Center, Houston

4. JMI Laboratories, North Liberty, Iowa

5. Department of Chemistry and Waksman Institute, Rutgers University, Piscataway, New Jersey

6. Division of Infectious Diseases, Alpert Medical School at Brown University, Providence, Rhode Island

7. College of Pharmacy, University of Illinois at Chicago

8. Division of Pediatric Infectious Diseases, Washington University, St. Louis, Missouri

9. Division of Geographic Medicine and Infectious Diseases, Tufts Medical Center and Tufts University School of Medicine, Boston, Massachusetts

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Microbiology (medical)

Link

http://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciz089/28556340/ciz089.pdf

Reference68 articles.

1. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE;Rice;J Infect Dis,2008

2. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America;Boucher;Clin Infect Dis,2009

3. World Health Organization. Antibacterial agents in clinical development: an analysis of the antibacterial clinical development pipeline, including tuberculosis. 2017. Available at: http://apps.who.int/iris/bitstream/10665/258965/1/WHO-EMP-IAU-2017.11-eng.pdf. Accessed 8 December 2017.

4. Infectious Diseases Society of America. Bad bugs, no drugs: as antibiotic discovery stagnates, a public health crisis brews. Available at: http://www.idsociety.org/uploadedFiles/IDSA/Policy_and_Advocacy/Current_Topics_and_Issues/Antimicrobial_Resistance/10×20/Images/Bad%20Bugs%20no%20Drugs.pdf. Accessed 5 June 2018.

Cited by 118 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. “Antibacterial properties of nine indium(III) complexes of substituted pyrazoles/pyrazolate and the structural and solution characterization of the mer- and trans‑indium(III) complexes of 4-Me-pzH”;Journal of Inorganic Biochemistry;2024-01

2. Genome mining ofStreptomycesfor the discovery of low-resistance antibiotics;2023-12-29

3. Safety and effectiveness of fifth generation cephalosporins for the treatment of methicillin-resistant staphylococcus aureus bloodstream infections: a narrative review exploring past, present, and future;Expert Opinion on Drug Safety;2023-12-25

4. Focusing on antimicrobial resistant infections –are we missing the forest for the trees and the patients for pathogens?;Frontiers in Antibiotics;2023-12-19

5. Guiding antimicrobial stewardship through thoughtful antimicrobial susceptibility testing and reporting strategies: an updated approach in 2023;Journal of Clinical Microbiology;2023-11-21